Protagonist Therapeutics (PTGX) Operating Expenses (2015 - 2026)

Protagonist Therapeutics has reported Operating Expenses for 12 years, with the latest figure at $60.0 million in Q1 2026.

• Quarterly Operating Expenses rose 26.0% year-over-year to $60.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $216.5 million (up 19.91% YoY) and the FY2025 annual result came in at $204.1 million, up 12.42% from the prior year.
• Operating Expenses rose to $60.0 million in Q1 2026 per PTGX's latest filing, from $57.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $60.0 million in Q1 2026 and troughed at $32.3 million in Q3 2022.
• A 5-year average of $44.6 million and a median of $43.9 million in 2024 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 55.02% in 2022, down 26.94% in 2022.
• Over 5 years, Operating Expenses stood at $36.5 million in 2022, then gained by 1.19% to $37.0 million in 2023, then gained by 18.69% to $43.9 million in 2024, then surged by 31.77% to $57.8 million in 2025, then increased by 3.85% to $60.0 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $60.0 million, $57.8 million, and $51.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.